Cargando...
Treatment of hepatitis C with an interferon-based lead-in phase: A perspective from mathematical modeling
BACKGROUND: The standard of care for hepatitis C virus (HCV) genotype 1 is a protease inhibitor (telaprevir or boceprevir) combined with pegylated interferon and ribavirin (P/R). A lead-in phase of P/R therapy before addition of the protease inhibitor has been used, with the aim of improving respons...
Guardado en:
| Autores principales: | , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2014
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4101064/ https://ncbi.nlm.nih.gov/pubmed/24434478 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3851/IMP2725 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|